|
|
3838 Medical Drive
San Antonio, TX 78229 USA
phone:210-615-6501
fax:210-615-6508
|
|
| Symbol |
Private |
| Founded |
2005 |
| Employees |
10 |
|
|
| www.senomedical.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Laser Opto-Acoustic Imaging for Cancer Diagnosis and Treatment |
|
| Management |
| Janet Campbell , Chairman and CEO; Ron Branstetter , President and COO; Nicholas Rockecharlie , Vice President and CFO; William F. Keane , M.D., Medical Director and CMO; Don Herzog , Director of Engineering; Barbara Lind , Vice President Corporate Development |
| |
|
|
| |
|
| Keywords |
| cancerous tumor detection, laser opto-Imaging based diagnostics, oncology |
|
|
|
| Description |
|
Seno Medical Instruments is a cancer focused company. It aims at the commercialization of a new modality in cancer screening and diagnosis: laser opto-acoustic imaging. This technology enables functional imaging that detects the presence and progression of cancerous tumors |
|
| Products / Services |
Seno's patented technology, optoacoustics, uses dual-wavelength lasers to pulse light into tissue. If a tumor is present, the lesion absorbs this light energy and creates a 3-D sound wave. The resulting acoustic wave is imaged in real-time.Seno's product will be used as an adjunct to mammography.Seno's functional imaging device detects lesions 5X smaller than mammography and distinguishes between malignant (cancer) and benign (non-cancer) lesions non-invasively. It reveals the essential cancer indicators; the presence or absence of blood and the existence of angiogenesis--blood vessels grown by the body to feed a cancerous lesion.
|
|
| Technology / Differentiation |
| Seno's imaging modality uniquely informs the user (physician/researcher) whether a lesion is cancerous by revealing the two basic causes of cancer: the growth of blood vessels, angiogenesis, and the absence of oxygen.Seno targets all solid
cancerous tumors. Seno's device operates at the push of the button to capture the image and provide information for cancer diagnosis. Seno's devices are portable and can be used for other functional applications such as prostate, ovarian or cervical cancers. |
|
| Market / Customers |
The target market for the breast cancer diagnostic technology is estimated to be $5.9 billion dollars in North America alone.
|
|
| Status |
| Pre- prototypes and core patents on opto-acoustic technology have been acquired and two other patents have been licensed for future patents. This will allow for potential follow-on applications, including imaging for the earliest detection of cancer of the ovary, bladder, prostate, colon and melanoma as well as unstable plaque (cardiovascular). The company has also launched its First-Ever Commercially Available Opto-Acoustic Small Animal Imaging Research System. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members